RoActemra
FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease
March 5, 2021Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …
Roche teams with DH for drug repurposing trial
January 6, 2016Research and Development DH, NIHR, Off Patent Drugs Bill, Off-Patent Drugs Bill, RoActemra, Roche, drug repurposing, tocilizumab
Roche and the UK Department of Health have launched a trial, to explore whether one of the company’s treatments for …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
RoActemra superior to Humira as single-agent therapy
June 7, 2012Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA
Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …
Roche’s RoActemra beats Humira in arthritis study
March 5, 2012Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis
Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …
NICE gives partial recommendation for RoActemra
December 14, 2011Sales and Marketing RoActemra, Roche
Roche’s patient access scheme has persuaded NICE to recommend RoActemra in childhood arthritis under certain circumstances. In its final guidance …
NICE recommends RoActemra for early use in arthritis
October 13, 2011Sales and Marketing NICE, RoActemra
NICE has recommended Roche’s drug RoActemra be used at an earlier stage for some arthritis patients. In draft guidance NICE …
NICE wants more RoActemra data for juvenile idiopathic arthritis
August 9, 2011Medical Communications NICE, RoActemra, Roche
NICE has requested more evidence from Roche for RoActemra in childhood arthritis. RoActemra (tocilizumab) is being assessed for the treatment …
NICE thumbs up for Roche arthritis drug
July 2, 2010Sales and Marketing NICE, RoActemra, Roche
NICE has given preliminary approval to Roche’s RoActemra as an additional option for the treatment of moderate to severe rheumatoid …
Roche halts ocrelizumab trials
March 8, 2010Research and Development RoActemra, ocrelizumab, rheumatoid arthritis
The future of Roche and Biogen Idec’s rheumatoid arthritis drug ocrelizumab has been thrown into doubt after the manufacturers decided …
NICE asks Roche for RoActemra cost data
March 5, 2010Sales and Marketing RoActemra, Roche
Roche’s attempts to secure NICE approval for rheumatoid arthritis drug RoActemra have hit another hurdle. NICE’s independent appraisal committee has …
FDA approves Roche’s Actemra
January 11, 2010Sales and Marketing Actemra, RoActemra, Roche, US, rheumatoid arthritis
Roche’s Actemra has been approved in the US for the treatment of moderately to severely active rheumatoid arthritis (RA) and …
NICE still saying ‘no’ to Roche’s RoActemra
December 17, 2009Sales and Marketing NICE, RoActemra, Roche
Roche will have to present a stronger case for arthritis drug RoActemra in order to gain approval, according to NICE. …
RoActemra approved in Europe
January 29, 2009Sales and Marketing RoActemra, Roche
The European Commission has approved Roche's RoActemra as a treatment for rheumatoid arthritis. Schering-Plough's Remicade, Wyeth's Enbrel and Abbott's Humira …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
